ANO3: A Protein with Potential as A Drug Target Or Biomarker (G63982)

Target Name: ANO3

NCBI ID: G63982

ANO3

ANO3: A Protein with Potential as A Drug Target Or Biomarker

ANO3 (ANO3_HUMAN) is a protein that is expressed in the human placenta and has been shown to play a role in the development and progression of various diseases, including cancer. As a drug target or biomarker, ANO3 has significant potential for the development of new treatments for a variety of diseases.

ANO3 is a member of the superfamily of ANO/ANO4 (Ano-6) proteins, which are characterized by the presence of a nucleotide-binding oligomerization domain (NBD) and a nucleotide-binding oligomerization domain-like (NBO) region. ANO3 is unique in that it contains a unique NBO region that is specific to ANO3 and allows it to interact with small molecules in a unique way.

The NBO region of ANO3 is made up of a series of conserved amino acids that form a looped structure that is able to bind to small molecules with specificity. This structure allows ANO3 to interact with small molecules that are toxic to cells and are often used as drugs or toxins. However, ANO3 is also able to interact with small molecules that are not toxic to cells and can have a beneficial effect on health.

One of the unique features of ANO3 is its ability to interact with small molecules that are involved in cell signaling pathways. This allows ANO3 to play a role in the development and progression of diseases that are caused by disruptions in these signaling pathways, such as cancer.

ANO3 has also been shown to play a role in the regulation of cellular processes that are important for normal development and growth. For example, ANO3 has been shown to be involved in the regulation of cell cycle progression and in the development of cancer.

In addition to its potential role in the development and progression of diseases, ANO3 also has significant potential as a drug target or biomarker. Because ANO3 is able to interact with small molecules that are involved in cell signaling pathways, it has been shown to be a promising target for the development of new drugs for a variety of diseases.

One of the challenges in developing new drugs for ANO3 is the difficulty of predicting the effects of these drugs on the target protein. This is because ANO3 is a protein that is expressed in a variety of tissues and conditions, and it is not clear how the effects of drugs will be specific to ANO3.

To address this challenge, researchers have used a variety of techniques to study the behavior of ANO3 and to understand its interactions with small molecules. These techniques have allowed researchers to identify specific small molecules that are able to interact with ANO3 and to understand how these interactions are responsible for the effects of drugs on the target protein.

In addition to these studies, researchers have also used techniques such as biochemical assays and cell-based assays to study the effects of drugs on the behavior of ANO3. These studies have allowed researchers to gain a better understanding of the specific mechanisms by which ANO3 is involved in the development and progression of diseases.

Overall, ANO3 is a protein that has significant potential as a drug target or biomarker. Its unique NBO region and its ability to interact with small molecules that are involved in cell signaling pathways make it an attractive target for the development of new treatments for a variety of diseases. While further research is needed to fully understand the specific mechanisms by which ANO3 is involved in the development and progression of diseases, its potential as a drug target or biomarker is an exciting area of research that is being actively explored.

Protein Name: Anoctamin 3

Functions: Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylcholine and galactosylceramide (By similarity). Seems to act as potassium channel regulator and may inhibit pain signaling; can facilitate KCNT1/Slack channel activity by promoting its full single-channel conductance at very low sodium concentrations and by increasing its sodium sensitivity (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity (PubMed:21984732)

The "ANO3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANO3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets